ILC1-derived IFN-γ balanced out the effect of IL-33 mediated ILC2 activation within visceral AT (Oboki et al., 2010), providing an in situ negative regulators of ILC2 anti-obesity effects. The gene discussed is IL33; the disease is obesity due to melanocortin 4 receptor deficiency.